BioWorld

May 30, 2008

Kosan's Cancer Pipeline Attracts $5.50 Per Share BMS Buyout Bid

Kosan Biosciences Inc. is being snatched up by Bristol-Myers Squibb Co. for $5.50 per share, becoming the latest acquisition as big pharma struggles to fill dwindling pipelines. (BioWorld Today) Read More

FDA Documents Critical of Ligand's Promacta

Onconase Misses Endpoint, Rolling NDA to Proceed

NewCo News: EnzymeRx Makes a $14 Million Start with Uricase Acquisition

Drug Labeling Rule Proposed for Those Pregnant, Breastfeeding

Favrille Laying Off 132 After Specifid Fails Pivotal Trial

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

Janssen Pharmaceutica reports new TMEM175 activators

BioWorld Science

Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...

Cancer specter looming, Abtect effect in UC wallops Abivax

BioWorld

Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...

EASL spotlight: TUNE-401 advances epigenetic silencing in HBV

BioWorld

Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most...